These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34237324)

  • 41. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical features and natural history in adults with IgA nephropathy.
    D'Amico G
    Am J Kidney Dis; 1988 Nov; 12(5):353-7. PubMed ID: 3055956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relation between biological IgA abnormalities and mesangial IgA deposits in isolated hematuria in childhood.
    Davin JC; Foidart JB; Mahieu PR
    Clin Nephrol; 1987 Aug; 28(2):73-80. PubMed ID: 3308233
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IgA nephropathy following COVID-19 vaccination: challenges and perspectives.
    Niel O; de la Fuente Garcia I
    Pediatr Nephrol; 2022 Jul; 37(7):1697-1698. PubMed ID: 35352190
    [No Abstract]   [Full Text] [Related]  

  • 45. [Eczematiform eruption after Pfizer-BioNTech COVID-19 vaccine].
    Bekkali N; Allard T; Lengellé C; Estève E
    Therapie; 2021; 76(4):364-365. PubMed ID: 34272069
    [No Abstract]   [Full Text] [Related]  

  • 46. Pharmacology Focus: Pfizer-BioNTech's COVID-19 Vaccine for Children 5 to 11 Years of Age.
    Brumels K; Jensen-Bender W
    S D Med; 2022 Jan; 75(1):36-37. PubMed ID: 35015942
    [No Abstract]   [Full Text] [Related]  

  • 47. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.
    Ostadgavahi AT; Booth R; Sisson G; McMullen N; Warhuus M; Robertson P; Miller M; Allen WC; El Sherif M; Brownlie R; Falzarano D; Richardson CD
    J Infect Dev Ctries; 2021 May; 15(5):653-656. PubMed ID: 34106888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New-onset immunoglobulin-A nephropathy post severe acute respiratory syndrome-coronavirus-2 infection indicates rapidly progressive glomerulonephritis.
    Yonishi H; Katada R; Kofune K; Kusunoki Y; Ikeda N; Ueno N; Teramoto K; Takeji M
    Nephrology (Carlton); 2022 Jun; 27(6):542-543. PubMed ID: 34811854
    [No Abstract]   [Full Text] [Related]  

  • 50. Acute renal failure in IgA nephropathy: aggravation by gross hematuria due to anticoagulant treatment.
    August C; Atzeni A; Köster L; Heidenreich S; Lang D
    J Nephrol; 2002; 15(6):709-12. PubMed ID: 12495289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine.
    Ackerman M; Henry D; Finon A; Binois R; Esteve E
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e423-e425. PubMed ID: 33783017
    [No Abstract]   [Full Text] [Related]  

  • 52. [Multicenter investigation of therapeutic status of children with IgA nephropathy in China].
    Working Group for National Survey on Status of Diagnosis and Treatment of Childhood Renal Diseases
    Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):486-90. PubMed ID: 24267127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
    Maas RJ; Gianotten S; van der Meijden WAG
    Am J Kidney Dis; 2021 Aug; 78(2):312. PubMed ID: 33992727
    [No Abstract]   [Full Text] [Related]  

  • 54. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
    Nojszewska M; Kalinowska A; Adamczyk-Sowa M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
    Komaba H; Wada T; Fukagawa M
    Am J Kidney Dis; 2021 Sep; 78(3):469-470. PubMed ID: 34023417
    [No Abstract]   [Full Text] [Related]  

  • 56. IgA nephropathy suspected to be combined with Fabry disease or Alport syndrome: a case report.
    Hao W; Ao L; Zhang C; Zhu L; Xie D
    J Int Med Res; 2020 Mar; 48(3):300060519891290. PubMed ID: 31840555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [IgA nephropathy, isolated hematuria and renal biopsy].
    Erben J
    Vnitr Lek; 2003 Nov; 49(11):837. PubMed ID: 14689676
    [No Abstract]   [Full Text] [Related]  

  • 58. Thin-basement-membrane nephropathy in adults with persistent hematuria.
    Tiebosch AT; Frederik PM; van Breda Vriesman PJ; Mooy JM; van Rie H; van de Wiel TW; Wolters J; Zeppenfeldt E
    N Engl J Med; 1989 Jan; 320(1):14-8. PubMed ID: 2909874
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of SARS-CoV-2-Specific IgG and IgA in Serum and Milk with Different SARS-CoV-2 Vaccines in Breastfeeding Women: A Cross-Sectional Study in Northern Spain.
    Lechosa-Muñiz C; Paz-Zulueta M; Mendez-Legaza JM; Irure-Ventura J; Cuesta González R; Calvo Montes J; López-Hoyos M; Llorca J; Cabero-Pérez MJ
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine.
    Jedlowski PM; Jedlowski MF
    Dermatol Online J; 2021 Jan; 27(1):. PubMed ID: 33560802
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.